antibody

FITC-linked Antibody to Coagulation Factor VIII (F8)

MBS2017764

0.1 mg

255 USD

polyclonal

rabbit

FITC

western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation

Antibody

FITC-linked Antibody to Coagulation Factor VIII (F8)

[Coagulation Factor VIII (F8)]

[coagulation factor VIII isoform 1; Coagulation factor VIII; coagulation factor VIII; Factor VIII; procoagulant component; coagulation factor VIII; Procoagulant component]

[F8]

[F8; F8; Cf8; Cf-8; FVIII; Cf8; F8c]

FA8_MOUSE

Polyclonal

Rabbit

2319

Antigen-specific Affinity Chromatography

Supplied as solution form in PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.

0.34 mg/ml

Storage: Avoid repeated freeze/thaw cycles. Store at 4°C for frequent use. Aliquot and store at -20°C for 12 months. Stability Test: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed.The loss rate is less than 5% within the expiration date under appropriate storage condition. Note: As fluorescence can photobleach when exposed to light, so the antibody must be protected from light.

Western Blot (WB), Immunohistochemistry (IHC), Immunocytochemistry (ICC), Immunoprecipitation (IP).

Western blotting: 0.5-2 ug/mL;1:170-680. Immunohistochemistry: 5-20 ug/mL;1:17-68. Immunocytochemistry: 5-20 ug/mL;1:17-68. Optimal working dilutions must be determined by end user.

Organism Species: Mus musculus (Mouse). Source: Antibody labeling. Label: FITC. Traits: Liquid. Immunogen: Recombinant F8 (His1854~Leu1988+LASTYRLG) expressed in E.coli.

FITC Antibody

238624180

NP_032003.2

NM_007977.2

Q06194

Blood Clotting Cascade Pathway (198388); Complement And Coagulation Cascades Pathway (198335); Complement And Coagulation Cascades Pathway (83270); Complement And Coagulation Cascades Pathway (484); Formation Of Fibrin Clot (Clotting Cascade) Pathway (925989); Hemostasis Pathway (925961); Intrinsic Pathway (925991); Platelet Activation, Signaling And Aggregation Pathway (925971); Platelet Degranulation Pathway (925988); Response To Elevated Platelet Cytosolic Ca2+ Pathway (925986)

F8: Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa. Defects in F8 are the cause of hemophilia A (HEMA). A disorder of blood coagulation characterized by a permanent tendency to hemorrhage. About 50% of patients have severe hemophilia resulting in frequent spontaneous bleeding into joints, muscles and internal organs. Less severe forms are characterized by bleeding after trauma or surgery. Of particular interest for the understanding of the function of F8 is the category of CRM (cross-reacting material) positive patients (approximately 5%) that have considerable amount of F8 in their plasma (at least 30% of normal), but the protein is non- functional; i.e. the F8 activity is much less than the plasma protein level. CRM-reduced is another category of patients in which the F8C antigen and activity are reduced to approximately the same level. Most mutations are CRM negative, and probably affect the folding and stability of the protein. Belongs to the multicopper oxidase family. 2 isoforms of the human protein are produced by alternative splicing. Protein type: Secreted; Secreted, signal peptide. Cellular Component: extracellular space; extracellular region. Molecular Function: copper ion binding; metal ion binding; serine-type endopeptidase activity; oxidoreductase activity. Biological Process: platelet activation; hemostasis; acute-phase response; proteolysis; blood coagulation; blood coagulation, intrinsic pathway

0.1 mg

255 USD

0.2 mg

390

1 mg

935